Jing Zhang
Position title: Professor
Email: Zhang@oncology.wisc.edu
Phone: 608-263-1147
Address:
McArdle Laboratory for Cancer Research
Cell signaling in hematopoiesis and leukemogenesis
- Address
- 7453 WIMR II, 1111 Highland Avenue
- Education
- 1995, Biochemistry and Molecular Biology, Beijing University, China, Postdoctoral Research: Whitehead Institute for Biomedical Research, Boston, MA
- Lab Website
- https://mcardle.wisc.edu/faculty/jing-zhang/
- Department
- McArdle Laboratory for Cancer Research
- Research Interests
- Cell signaling in hematopoiesis and leukemogenesis
- Research Fields
- Disease Biology, Mouse and Other Mammals
Research Description:
The research program in my lab focuses on cell signaling, in particular Ras signaling, in hematopoiesis and leukemogenesis. We generated and characterized multiple genetically engineered mouse models for oncogenic Ras-driven blood cancers, including juvenile monocytic leukemia, chronic myelomonocytic leukemia and its transformation to acute myeloid leukemia, multiple myeloma, and early T cell precursor acute lymphoblastic leukemia. We use these models along with cell lines and patient samples to:
1. Study how genetic mutations alter hematopoietic stem and progenitor cell functions to promote blood cancers
2. Investigate disease mechanisms using multi-Omics approach
3. Develop mechanism-based novel combination targeted therapies and immunotherapies
4. Validate therapeutic strategies in preclinical models in vitro and in vivo
Representative Publications:
Search PubMed for more publications by Jing Zhang
You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022 Feb 17;139(7):1066-1079. doi: 10.1182/blood.2021012519. PubMed PMID: 34699595; PubMed Central PMCID: PMC8854684.
Wen Z, Yun G, Hebert A, Kong G, Ranheim EA, Finn R, Rajagoplan A, Li S, Zhou Y, Yu M, Damnernsawad A, Roose JP, Coon JJ, Wen R, Wang D, Zhang J. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors. Blood. 2021 Jun 10;137(23):3259-3271. doi: 10.1182/blood.2020009082. PubMed PMID: 33512434; PubMed Central PMCID: PMC8351901.
Wen Z, Rajagopalan A, Flietner ED, Yun G, Chesi M, Furumo Q, Burns RT, Papadas A, Ranheim EA, Pagenkopf AC, Morrow ZT, Finn R, Zhou Y, Li S, You X, Jensen J, Yu M, Cicala A, Menting J, Mitsiades CS, Callander NS, Bergsagel PL, Wang D, Asimakopoulos F, Zhang J. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood. 2021 Jan 7;137(1):61-74. doi: 10.1182/blood.2020007156. PubMed PMID: 32640012; PubMed Central PMCID: PMC7808014.
You X, Kong G, Ranheim EA, Yang D, Zhou Y, Zhang J. Unique dependence on Sos1 in KrasG12D -induced leukemogenesis. Blood. 2018 Dec 13;132(24):2575-2579. doi: 10.1182/blood-2018-09-874107. Epub 2018 Oct 30. PubMed PMID: 30377195; PubMed Central PMCID: PMC6293870.
Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang J. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest. 2014 Jun;124(6):2762-73. doi: 10.1172/JCI74182. Epub 2014 May 8. PubMed PMID: 24812670; PubMed Central PMCID: PMC4038579.
Wang J, Kong G, Liu Y, Du J, Chang YI, Tey SR, Zhang X, Ranheim EA, Saba-El-Leil MK, Meloche S, Damnernsawad A, Zhang J, Zhang J. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions. Blood. 2013 Jun 27;121(26):5203-7. doi: 10.1182/blood-2012-12-475863. Epub 2013 May 17. PubMed PMID: 23687087; PubMed Central PMCID: PMC3695364.